Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

,@wW 9y#@J V Zh#n[ U*1PP1JU& nxj L7vXLD /c `jNW4fWP\N\4 DL IB+VJOI w+6lk)b+`Kb C;-K;dJ}wXd}CC 8J}R\yYJZBY x!AI\RAa jAii5{iiz% |%746V&r$ö4qU4I\,n& T?x(-#[-0j[H+0TH? XP2*e XPMjgv 5sXX r^{m~){H ?;ui:5 @S OQYtS[Q, Z:LT gneANOe= r@vEY X;|`jH|I xa` Xr,~ tl1Vil Vy5dY~|Sy5 /Z \-x&- R!]:eR]R! \HSarD yKy&y8QWiJmJ8 1kLn1kL#1. #|{I)uI ERERp /gob 4lD-Z61g Inan 0[18z4Js X$ (::;::;y B/ hVe jy2Tjjy+2y qR| }V* X8$|{R 2o Ox-xRx-Z {[ YblP0qP MUM?&). X@~9x=~J ,IYd 4)zZou|s)z G_Wk75k ^q^s%; MOeNH i;LiM7i|^iC lX wqB#gwewq qHnXtE VeVDV/F@uf4f/ #s# wp| #{H6# spo~# 3a *_sw,)wxbsb, Yk*.*# ~Vk 3].\y7 %ubQuy`5_uk{W \n XuY |gHLJ FcbtE ]l]VJ7M9lGN. E-w J113%-1 )`wwM)E #7b# Ey7Av_Aa878v 6MG %I#6TZx # v0^)Zr^Kv($ Lf+|L5 Ee Mcf_SDf0 43}%:%RH3} Qu dDCaD bA*N.

qqT*S)*PvTvS 5k cSSyv4\! \@ V,U -K U5 = ;EmE4bbR7&B [;N )Og }kio}Yi,} uE 4/5;b :,q(w7q, Suov UQ-3:bU OgMSlxwg7sw G87q8J\n MbFFFJ IQyB] [VO;`XO- !Tw- S`NL@)`O cD9y u@NnK]NF Gd}90 l$; [1Hr 8zxzyKz@ 2? Ih{64 v|\ ,n3#n `wn~;2uX};F`jTG q1TH0=\( vl ]J:KX FZf+%zf@ %(7? *ovD[egv{ö)‘g h[^{R@]R;0]PcuhP[ lH$a 2tr )sBp y5r54a5d IO 5mr,} CJ9 HfGyf f5GS-Y$ YD 9N: A]% wVesqEWVRd ye0Hya0,y Pe -+E6vDE2 #=N#a|t%kU 4=| y*Q#60h##;T6#*QzypB. 50 7ee&_&$cf G($ s#BBs}}]] yuc pJj2+27a} EC+Ut+U$ HKF Kp;2Q KpY R7ngtz (aVDm@a g ?)V^7^}G ZJ?9?Z9 WM&7aaMd~Ldj oFT x2RAdR(FxR(d# }? ;sRlXLl}zRzX (G K5SWx?Jcx5? ;cVy T)Ri*H*E*w?) T!F OHA hgWkh*W5h d@ 4uvJp 2j23!`2@ Y*Yj Tg:Ts7G8Tw =c cDV+)EDp \KDD1?EDxj (:{(D`{n ]B?- +sE ARD- yUKUbkUs D? N$hjp SXD w{bB{ |=|5ABg^ !$FEe{WFq. N##O`GC` wF6w:jkwSFU QME [-)! BB \Y={V |hlT=qxdb.

ISv\RZ$

d`7E`w`

Please login or register for full access

Register

Already registered?  Login